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ABSTRACT
The synthetic flavonoids EMD 23188 and EMD 49209, developed
as T4 analogs, displace T4 from transthyretin, and in vitro they inhibit
59-deiodinase activity. In vivo EMD 21388 causes tissue-specific
changes in thyroid hormone metabolism. In tissues that are depen-
dent on T3 locally produced from T4, total T3 was diminished. It was
not known whether it was the presence of EMD interfering with
59-deiodinase type II in tissues or the decreased T4 (substrate) avail-
ability that caused the lowered T3. To study whether the flavonoids
enter tissues and, if this were the case, whether they enter tissues
similarly, [125I]EMD 49209 together with [131I]T4 were injected into
female rats and rats pretreated with EMD 21388. Tissues were ex-
tracted and submitted to HPLC. [125I]EMD 49209 disappeared
quickly from plasma and enters peripheral tissues; peak values were
reached after 0.25–0.5 h. Then [125I]EMD 49209 appeared in the
intestines (after 6 h 40% of the dose). Tissue uptake of [131I]T4 was
very rapid. EMD 21388 pretreatment caused an increase in the ex-
cretion of [125I]EMD 49209 into the intestines (40% after 0.25 h). The
uptake of [131I]T4 increased, but not high enough to ensure normal
tissue T4 concentrations. In the 59-deiodinase type II-expressing tis-
sues, no [125I]EMD 49209 could be detected. We conclude that the
decrease in T3 locally produced from T4 is caused by the shortage of
T4 as substrate and not to a direct effect of EMD on the activity of
59-deiodinases I and II. (Endocrinology 138: 79–84, 1997)
FLAVONOIDS, naturally occurring secondary metabo-lites and dyes in plants, have been shown to be themain
constituents of folk remedies used for the treatment of thy-
roid and other hormonal disorders (1–4). Early studies in-
dicated that natural flavonoids are able to induce goiter.
Together with an increase in thyroid weight, a reduced io-
dide organification was found (5). Recently, it has been
shown that flavonoids as constituents in a staple food, the
African millet, are the cause of goiter and associated disor-
ders (6). To study the interactions of flavonoids with the
iodine-thyroid hormone system, a model was chosen in the
form of synthetic flavonoids. These flavonoids were devel-
oped by means of molecular drug design (1, 2, 4). The syn-
thetic flavonoids 3-methyl-49,6-dihydroxy 39,59-dibromo-fla-
vone (EMD 21388) and 3-methyl-49,6-dihydroxy 39,59-
diiodo-flavone (EMD 49209), both T4 analogs, are potent
inhibitors of the binding of T4 to transthyretin (TTR), but not
to other plasma proteins (1, 2, 7, 8). These specific TTR com-
petitors are useful tools to study distribution and kinetics of
T4, as the synthetic flavonoids redistribute endogenous T4
without the need to add exogenous (pharmacological) T4.
EMD 21388 in vitro inhibits 59-deiodinase type I in rat liver
microsomes (9). In vivo studies with long term treatment of
rats with EMD 21388 iv (20 mmol/kg BWzday) showed that
this synthetic flavonoid interferes with thyroid hormone se-
cretion, turnover, and metabolism in several tissues in dif-
ferent ways (10–13). From the double isotope equilibrium
study (10), it was clear that in all tissues investigated T4
concentrations decreased. In those tissues that express the
59-iodothyronine deiodinase isoforms, liver, pituitary, testis,
thymus, brown adipose tissue, brain, cerebellum, and hy-
pothalamus, the amounts of T3 locally produced from T4
were decreased. The ratio of [125I]T3/[
125I]T4 was unchanged.
It was not known whether these effects of EMD 21388 were
due to inhibition of deiodinase isoforms or to a shortage of
the amount of substrate, T4. As there were tissue-specific
changes that differed from the effects expected from work in
vitro, especially regarding the activity of the different 59-
deiodinase isoforms, it appeared important to assesswhether
the flavonoid enters into all organs and, if so, whether it does
so similarly in all tissues.
To investigate this phenomenon we studied the distribu-
tion of EMD 49209, a congener of EMD 21388 in which
bromide is replaced by iodide substituents on the phenolic
ring. These iodide atoms were radiolabeled by an exchange
labeling reaction with 125I. We used this [125I]radioactive
flavonoid togetherwith [131I]T4 to address the question of the
changes in the different T4 distribution pools in the intact
animal during long term treatment with the flavonoid. We
compared their tissue distributions for up to 6 h after a bolus
injection in rats pretreated with EMD 21388 iv for 14 days
and in rats receiving the vehicle without EMD 21388
pretreatment.
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Materials and Methods
Animals
The experiments were approved by the local committee on animal
care. Two groups of female Wistar rats (CPB/WU, Iffa Credo, Brussels,
Belgium), about 180 g BW,were used. The ratswere individually housed
at 22 C, with alternating 14-h light and 10-h dark periods. They were fed
the American Institute of Nutrition Diet (14). Potassium iodide was
added to the drinkingwater (10mg/liter). One group (Exp B; n5 7) was
given EMD 21388 twice a day iv via a cannula that was inserted into the
right jugular vein and extended to the right atrium (20 mmol/kg
BWzday) for 14 days. EMD 21388 (42.6 mg) was dissolved in 100 ml
sodium hydroxide (0.18 m), and saline was added directly to obtain 10
ml; the other group (Exp A; n 5 7) received the vehicle without EMD
21388 (10).
Preparation of radiolabeled compounds
EMD 49209 (10 mg/10 ml dimethylsulfoxide) was diluted with 40 ml
phosphate buffer (0.25m; pH 6.5). To 30 ml phosphate buffer (0.05m; pH
7.4) were added chloramine-T (10 mg/10 ml H2O) and 7.5 ml Na
125I (375
mCi); the mixture was vortexed for 2 min at room temperature. EMD
49209 was added immediately and vortexed for 1 min at room temper-
ature; the radiolabeling was stopped by the addition of 20 mg sodium
bisulfite in 10ml H2O, followed by 800ml H2O. Thismixturewas purified
by HPLC [Waters Associates, Milford, MA; with UV and radioactivity
detectors; Eurosfer-100C10, 5 mm, JF 17 column; flow rate, 1 ml/min;
gradient elutions A (5% acetonitril and 0.1% trifluoroacetic acid) and B
(95% acetonitril and 0.1% trifluoroacetic acid) with gradient program
0–30% B in 1.3 min, 30–90% B in 1.3–30 min, 90–100% B in 30–31 min].
EMD 49209 and its 125I-labeled derivate eluted at 20.8 min; a compound
containing an additional iodine substituent eluted at 23.6 min. The
respective fractions were collected and appropriately diluted. The spe-
cific activity of [125I]EMD 49209 was about 20 mCi/mg with a yield of
about 53%.
[131I]T4 was prepared freshly in our laboratory (15). The purity of the
radioactivity was assessed by HPLC just before use. 125I or percent 131I
was less than 0.1%, and no other labeled metabolites could be detected.
Experiments
On day 14 the rats received a bolus iv injection of 400 ml [125I]EMD
49209 (3 mCi) and [131I]T4 (5 mCi) in saline containing 5% normal rat
serum. This bolus injection of [125I]EMD 49209 and [131I]T4 was given 1 h
after the last iv injection of EMD 21388 (Exp B) or vehicle (Exp A); 0.25,
0.5, 1, 2, 3, 4, and 6 h after the injection the rats were bled and perfused
with saline. Tissues were removed, weighed, and counted. To investi-
gate whether [125I]EMD 49209 is metabolized, plasma and tissues were
extracted and subjected to HPLC chromatography following the same
extraction procedure andHPLCprotocol as those used for the separation
of iodothyronines (16). In all tissues analyzed, [125I]EMD49209 appeared
in the same retention time. With the exception of free 125I, no other
metabolites were detected. The extraction efficiency for the 125I and 131I
activities from all tissues was greater than 95%.
Plasma [125I]EMD 49209 and [131I]T4 disappearance rates and tissue
contents of [125I]EMD 49209 and [131I]T4 were determined. The percent
doses in tissues were corrected for trapped plasma (17). The intestines
of the rats were divided into five segments: three equal lengths of small
intestine, cecum, and colon; feces and urine were collected, and for all
of these fractions, the percent doses of 125I and 131I were determined.
In total, 30 different organs were dissected and processed. For the
sake of clarity, only those organs that contributed substantially to the
changes in the distribution of the radioactivity are shown, the other
organs are taken together and are shown as “rest.” The percent doses in
total blood, muscle, fat, skeleton, and skin were calculated according to
the relative contribution to body weight (18). The total contents of
radioactivity in the intestinal segments and feces were also calculated.
After decay of the 131I initially present in the plasma samples, the
concentrations of T4 and T3 were assessed by rat RIA, using
131I-labeled
T4 and T3, respectively, as tracers (19). Free T4 levels were measured by
ultrafiltration using Microcon 10 (Amicon, Danvers, MA) filters and
freshly labeled [131I]T4 (20). Plasma TSH was measured by the specific
RIA developed for the rat by theNIDDK (NIH, Bethesda,MD). RP-2was
used as a standard.
Results
Both groups of rats had a normal increase in body weight.
No toxic effects of EMD21388were observed (Exp B). Plasma
T4 and T3 decreased in the EMD 21388-treated rats by ap-
proximately 55% and 28%, respectively. Although the per-
centage of free T4 was higher, free T4 concentrations were the
same because of the lowered total plasma T4 levels. Plasma
TSH levels did not change (Table 1).
Exp A: controls or vehicle-treated rats
Distribution of [125I]EMD 49209. Figure 1A shows the disap-
pearance curves of [125I]EMD 49209 from plasma. Fifteen
minutes after the bolus injection, [125I]EMD 49209 appeared
in tissues (Table 2A). Peak values were reached between
15–30 min (Table 2A). The percent dose of [125I]EMD 49209
decreased in tissues with time. After 6 h, 45% of the dose of
[125I]EMD 49209 was found in the intestines (Table 2A). In
many tissues, such as brain, cerebellum, hypothalamus, and
medulla, the percent dose of 125I radioactivity is very low,
ranging from 0.0001–0.070% of the dose (Table 3). After
HPLC analysis, this activity appears to be iodide. In none of
these tissues could [125I]EMD 49209 be detected. The calcu-
lated tissue/plasma ratios of the individual tissues were
more or less constant during the 6 h, indicating that therewas
no accumulation for [125I]EMD 49209 (data not shown).
Distribution of [131I]T4. Figure 1B shows the disappearance of
[131I]T4 from plasma. [
131I]T4 disappeared rapidly, within the
first 5–10 min. The uptake of [131I]T4 by tissues was rapid,
especially that by liver (Table 2B). The percent dose of [131I]T4
in tissues decreased with time (Table 2B). In the intestines,
about 22% was found after 6 h (Table 2B).
Comparison between [125I]EMD 49209 and [131I]T4 distribution.
Clear differences in kinetic behavior were evident (Fig. 1C).
[131I]T4 disappeared more rapidly from plasma, within the
first 5–10 min. At the start, the percent dose of [125I]EMD
49209 was higher than that of [131I]T4, and then disappeared
at a slower rate than T4, but after 5–6 h, theywere at the same
level.
The uptake of [125I]EMD 49209 in tissues was much less
and slower than that of T4. There was a striking difference in
uptake in liver (Table 2, A and B). With time, there was a
TABLE 1. Body weight before and after treatment
Vehicle-treated rats EMD 21388-treated rats
BW (g) 180 6 4 179 6 5
BW after Rx 204 6 5 205 6 5
T4 (nM) 38 6 4 17 6 4
a
% Free T4 0.047 6 0.004 0.092 6 0.004
a
Free T4 (pM) 18 6 2 16 6 2
T3 (nM) 0.85 6 0.05 0.61 6 0.03
a
TSH (ng/ml) 0.55 6 0.07 0.60 6 0.11
Plasma thyroid hormone and TSH values of vehicle-treated and
EMD21388-treated rats.n5 7 for both groups.Values are themean6
SE.
a At least P , 0.05.
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small increase in the uptake of [125I]EMD49209 inmuscle and
skin, comparable with that of [131I]T4.
After 6 h the greatest differences were found between the
contents of [125I]EMD 49209 and [131I]T4 in liver and
intestines.
Exp B: pretreatment of rats with EMD 21388
Distribution of [125I]EMD 49209. The disappearance of
[125I]EMD 49209 from plasma was greatly enhanced by pre-
treatment with EMD 21388 (Fig. 1A). EMD 21388 treatment
resulted in an increase in the excretion of [125I]EMD 49209
into the intestines as well as into the urine (Table 2C). At the
first time point (0.25 h), 38% of the [125I]EMD 49209 was
already present in the intestines,mainly in the first part of the
jejunum (Fig. 2, I, II, and III). After 6 h, most of the [125I]EMD
49209was found in the intestines (54%) andurine (31%; Table
2C). The radioactivity in the urine consistedmainly of iodide,
indicating that this amount of [125I]EMD 49209 was metab-
olized or at least deiodinated. The percent dose of [125I]EMD
49209 in some organs was hardly detectable; after 6 h, no
[125I]EMD 49209 could be detected in brain, cerebellum, me-
dulla, or hypothalamus. Table 2C shows the percent dose of
[125I]EMD 49209 at the different time points.
Distribution of [131I]T4. The disappearance of [
131I]T4 from
plasma was increased compared to the T4 distribution in the
vehicle-treated rats (Fig. 1B). After 15 min, the uptake of T4 by
liver was very high (Table 2D). After 6 h, a large part of the T4
was still present in the liver and the various organs; the total
excretion was 40% (intestines, 24%; urine, 16%). After pretreat-
ment with EMD 21388, [131I]T4 distribution did not change
markedly; therewas lessT4 in thebloodandmore in theorgans,
and only a slight increase in excretion (Table 2D).
Comparison between [125I]EMD 49209 and [131I]T4 distribution.
Figure 1D shows that pretreatment with EMD 21388 abol-
ished the difference in plasma disappearance of [125I]EMD
49209 and [131I]T4 present during vehicle treatment. After 15
min, the uptake of [131I]T4 by liver was nearly 10 times higher
than that of [125I]EMD 49209 (Table 2, C and D). Figure 2
shows the presence of [125I] (Fig. 2A) and [131I] (Fig. 2B)
activities in gut fractions with time. After 6 h, approximately
40% of the 125I dose was found in intestinal contents and
feces, whereas only 25% of 131I was present. EMD 21388
treatment caused a shift in the appearance time of 125I in
intestinal fractions. At the first time point, 38% of the dose
was already present in the intestines.
Discussion
The T4 plasma disappearance and tissue distribution re-
sults for Exp A are in accordance with the data obtained by
our group in earlier studies, in which T4 metabolism was
measured under several experimental conditions and other
experimental set-ups, such as the double isotope equilibrium
technique (10, 13, 15, 16).
The two flavonoids used in this study were developed by
molecular drug design, directed toward the inhibition of the
hepatic 59-iodothyronine deiodinase. Both fulfill the criteria
necessary for the optimal inhibitory potency (4). The only
difference between these flavonoids is the two bromide at-
oms (EMD 21388) vs. the two iodide atoms (EMD 49209) in
the 39- and 59-positions. This makes it possible that EMD
49209 can be deiodinated by deiodinases; debromination of
EMD 21388 is less likely. That deiodination occurs can be
seen from the free 125I excreted in urine. This influences the
kinetic behavior, which means that the disappearance rate of
EMD 49209 is faster than that of EMD 21388; in the vehicle-
treated rats, it is about 10% (Exp A), and in EMD 21388-
pretreated rats, it is about 20% (Exp B).
From our study it is clear that the synthetic flavonoid,
[125I]EMD 49209, disappears very quickly from plasma and
enters tissues. However, the percent dose of the flavonoid in
the organs is never high and decreases with time. It can be
concluded from the rapid uptake of both compounds by the
liver that this organ functions as an essential part of the fast
pool. However, there is a discrepancy between T4 and the
flavonoid. T4 content as a percentage of the dose in the liver
is much higher than that of the flavonoid (with a high ex-
cretion into the intestinal lumen). This means that in liver,
many binding sites exist for T4, but not for the flavonoid.
It appears that EMD 49209 does not bind to intracellular
T4 binding sites; there is a rapid transfer from plasma via the
liver into the intestines. Also, EMD 21388 does not bind to
nuclear thyroid hormone receptor (Bernal, J., personal com-
FIG. 1. Disappearance of [125I]EMD 49209 and [131I]T4 from plasma.
A, [125I]EMD 49209 in vehicle-treated and EMD 21388-pretreated
rats. B, [131I]T4 in vehicle-treated and pretreated EMD 21388 rats. C,
[125I]EMD 49209 and [131I]T4 in vehicle-treated rats. D, [
125I]EMD
49209 and [131I]T4 in EMD 21388-pretreated rats.
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munication) and does not activate the human 59deiodinase
thyroid hormone-responsive element in LLC-PK1 kidney cell
line (Jacoks, T., personal communication). It is possible that
without binding to the thyroid hormone-binding sites, there
is no retention in tissues.Although these synthetic flavonoids
were developed by molecular drug design as T4 analogs
(1–4), the in vivo kinetic behavior of [125I]EMD 49209 is dif-
ferent from that of [131I]T4. This could be explained from the
fact that EMD 21388 and EMD 49209 bind only to TTR and
not to other plasma proteins, as is the case for T4 (8, 21). This
also can explain the differences in the behavior of [125I]EMD
49209 between vehicle-treated andpretreated rats; in vehicle-
treated rats, the tracer amount of [125I]EMD 49209 will be
totally bound to TTR, and its disappearance will be closely
related not only to the binding to TTR, but also to the half-life
of TTR. In the pretreated animals, the TTR is completely
occupied by the EMD 21388, and the larger part of this
flavonoid as well as [125I]EMD 49209 will exist in plasma in
the free form. It is surprising that the plasma disappearance
curves of EMD and T4 are very similar, whereas their tissue
distributions are essentially different.
The higher amount of flavonoid present in the liver will
induce hepatic enzymes, i.e. such as those involved in glu-
curonidation. This would lead to an increased metabolism
not only of the flavonoid itself, but also that of T4. It has been
shown that the most substantial metabolic pathway of nat-
ural flavonoids in mammals is conjugation with glucuronic
acid or sulfate (22, 23). The conjugates are excreted in bile and
urine. The material excreted by the bile can be hydrolyzed in
the intestines by themicroflora; the liberated flavonoids may
then be reabsorbed. We assume that this is also the case for
our synthetic flavonoids.
TABLE 2. Distribution of radioactivity, as percentage of the dose of [125I]EMD 49209 or [131I]T4 from 0.25–6 h after bolus injection
0.25 0.5 1 2 3 4 6
A) Distribution, as percentage of the dose of [125I]EMD 49209, in vehicle-treated rats, from 0.25–6 h after the bolus injection
Blood 72 60 53 42 31 28 18
Liver 7 9 6 6 4 3 2
Skin 4 6 7 8 8 10 9
Muscle 8 8 8 11 9 11 9
Fat 2 4 4 3 4 3 3
Skeleton 2 2 4 4 3 2 2
Rest 2 2 2 3 3 2 2
Intestines 5 9 17 25 32 33 45
Urine 0 0 0 1 6 8 10
B) Distribution, as percentage of the dose of [131I]T4, in vehicle-treated rats from 0.25–6 h after the bolus injection
Blood 42 31 34 25 27 21 21
Liver 29 30 23 19 16 15 14
Kidney 2 2 2 2 2 2 1
Skin 4 7 7 9 11 9 11
Muscle 7 8 10 9 11 9 11
Fat 1 4 4 3 4 3 3
Skeleton 3 4 3 3 3 3 3
Rest 2 3 4 3 4 3 3
Intestines 10 12 14 23 17 26 22
Urine 0 0 0 4 5 10 12
C) Distribution, as percentage of the dose of [125I]EMD 49209 after pretreatment with EMD 21388, from 0.25–6 h after the
bolus injection
Blood 37 22 15 14 13 9 3
Liver 5 6 2 2 2 2 1
Skin 7 8 6 9 8 9 2
Muscle 8 11 7 7 7 7 2
Fat 1 3 2 3 2 2 1
Skeleton 2 4 2 2 2 2 1
Rest 2 2 3 3 3 3 2
Intestines 39 46 50 53 45 48 56
Urine 0 0 13 8 20 18 31
D) Distribution, as percentage of the dose of [131I]T4, after pretreatment with EMD 21388 0.25–6 h after the bolus injection
Blood 27 24 24 25 19 18 9
Liver 42 41 29 24 20 21 19
Kidney 4 4 4 3 3 3 1
Skin 6 6 8 10 11 11 7
Muscle 8 6 12 13 16 15 11
Fat 5 5 6 6 4 4 5
Skeleton 2 3 3 3 3 3 2
Rest 3 4 5 5 6 6 5
Intestines 4 4 10 11 15 16 24
Urine 0 0 1 1 4 4 16
All time points are shown. In total, 30 different organswere dissected and processed. For the sake of clarity, only those organs that contributed
substantially to the changes in the distribution of the radioactivity are shown; the other organs are taken together and are shown as “Rest.”
The percent doses in total blood, muscle, fat, skeleton, and skin were calculated according to their relative contributions to the body weight
(18). The total contents of radioactivity in the intestinal segments and feces were calculated.
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Fromour results it is clear that the flavonoid does not cross
the blood-brain barrier; therefore, in our view this flavonoid
cannot be held directly responsible for the inhibition of 59-
deiodinase type II in brain, cerebellum, hypothalamus, and
medulla. Thus, the decrease in T3 locally produced in those
tissues should be due to the lowered amount of substrate (T4)
(10). The access of the flavonoid to the brain appears com-
pletely different from that of the peripheral tissues, indicat-
ing that T4 conformational homology is not sufficient to gain
access to the brain via the brain-blood barrier or the blood-
choriod plexus-cerebrospinal fluid barrier.
Despite the high amount of EMD 21388 in the liver [cal-
culated as: 0.305 (%dose [125I]EMD49209/g)3 1mmol (100%
dose) 5 3.05 nmol/g] compared to that of T4 (0.051 nmol/g)
(24), there is no indication that inhibition of 59-deiodinase
type I occurs, as deduced from the unchanged Lc[125I]T3/
[125I]T4 ratio in the liver (10). It seems likely that the fla-
vonoids do not reach the deiodinase compartment in tissues
despite high transient concentrations of reversible compet-
itive binding of the flavonoid to deiodinases. This is in con-
trast to other known inhibitors, such as PTU and iopanoic
acid, that bind irreversibly to the active site of the enzyme.
Acute and short term treatments with EMD 21388 dem-
onstrate the effects on the displacement of T4 from TTR,
transiently increasing free T4 and decreasing TSH (25–28),
whereas long term treatment results in changes in the met-
abolic pathway of thyroid hormones that cannot only be
accounted for by decreased binding of T4 by TTR. Therefore,
other mechanisms that have not yet been identified are likely
to be responsible (10). The most pronounced change is the
strong increase in intestinal excretion and the increased me-
tabolismby the deiodinative pathway, as concluded from the
increase in radioactivity in urine.
The differences between in vivo and in vitro effects of the
flavonoids can be attributed to the presence of plasma bind-
ing proteins in the in vivo situation and their absence in the
in vitro incubation system, leading to increased cellular fla-
vonoid concentrations in the in vitro situation. The properties
of the flavonoids make them valuable tools in studies of
intracellular thyroid hormone regulation in vitro, but also in
vivo by influencing T4 production, metabolism, and
excretion.
TABLE 3. Percent doses of [125I]EMD 49209 and [131I]T4 in
various organs of rats
% Dose of
[125I]EMD 49209 % Dose of [
131I]T4
0.25 6 0.25 6
Vehicle-treated rats
Brain 0.000 0.000 0.040 0.147
Cerebellum 0.000 0.000 0.007 0.021
Hypothalamus 0.000 0.000 0.001 0.007
Medulla 0.000 0.000 0.008 0.048
BAT 0.074 0.038 0.101 0.052
EMD 21388-treated rats
Brain 0.000 0.000 0.067 0.150
Cerebellum 0.000 0.000 0.016 0.032
Hypothalamus 0.000 0.000 0.004 0.032
Medulla 0.000 0.000 0.014 0.036
BAT 0.037 0.010 0.076 0.116
The first time point after the bolus injection is 0.25 h; the last is
6 h. Rats were killed, bled, and perfused. Tissues were homogenized,
counted, extracted, and submitted to HPLC. The percent dose in
tissues is corrected for trapped plasma.
FIG. 2. The radioactivity in five fractions [three lengths of small
intestines (I, II, III), cecum (IV), and colon (V)] of the intestines and
feces (Fc) at seven time points after the bolus injection in vehicle-
treated (C; open circles) and EMD 21388-pretreated (closed circles)
rats. Left row, 125I activity after a bolus injection of [125I]EMD 49209.
Right row, 131I activity after a bolus injection of [131I]T4. Note the
difference between the y-axis for the fractions and feces.
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